Valeant Pharmaceuticals has major plans for 2014, including the goal of becoming one of the world’s five-largest pharmaceutical companies. That goal, reports say, includes reaching a market value of more than $150 billion.
Valeant, based in Canada, has upped its market value from less than $3 billion in 2010 to its current value of $44 billion through major acquisitions.
Now, plans to merge with Actavis could now add yet another boost to its market value this year. Industry experts also note that a deal with Teva Pharmaceuticals could push Valeant in the right direction.
According to the head of healthcare research at Aegis Capital, Valeant’s $150 billion goal “is actually not unrealistic at all.”
”This transaction is going to happen in 2014, and it’s going to be a biggie,” he said.
Full Content: Businessweek
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Criticizes EU’s Tech Crackdown, Calls It ‘A Form of Taxation’
Jan 23, 2025 by
CPI
Meta Faces Fresh Allegations of EU Law Breaches in Subscription Service Rollout
Jan 23, 2025 by
CPI
European Commission Investigates Crypto Rules for Cross-Border Stablecoins
Jan 23, 2025 by
CPI
Senate Bill Aims to Ban Anti-Competitive Rent-Setting Software in Washington
Jan 23, 2025 by
CPI
Former CEO of Pioneer Natural Resources Sues FTC
Jan 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon